What is the NewAmsterdam Pharma product?
NewAmsterdam Pharma's primary lead product candidate is obicetrapib, an investigational, highly selective cholesteryl ester transfer protein inhibitor developed to treat elevated levels of low-density lipoprotein cholesterol. Evaluated in extensive phase 3 clinical trials such as BROADWAY and BROOKLYN, obicetrapib is designed as an effective adjunctive therapy to maximally tolerated statins, significantly reducing cardiovascular risks and improving lipid metabolism profiles.
Related FAQs
New Amsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing oral, transformative therapies for metabolic and cardiovascular diseases with high unmet medical needs.
Smirnoff and New Amsterdam are both popular, mass-market vodkas that serve different purposes for the casual drinker.
NewAmsterdam Pharma Company N.V. is a fully public biotechnology enterprise, with its common shares listed and actively traded on the Nasdaq Stock Exchange under the ticker symbol NAMS.
NewAmsterdam Pharma is a clinical-stage biopharmaceutical enterprise dedicated to developing oral, revolutionary therapies for patients with metabolic diseases and severe cardiovascular disorders who are poorly served by existing standard treatments.
The popular New Amsterdam brand of spirits (comprising New Amsterdam Vodka, gin, and ready-to-drink canned cocktails) is owned by E. & J. Gallo Winery, operating through its specialized beverage division known as Spirit of Gallo. E. & J.
New Amsterdam, the historic 17th-century Dutch colonial fortified settlement that served as the capital of New Netherland, is located today within the boundaries of modern-day New York City, United States.
NewAmsterdam Pharma Company N.V. maintains a multi-billion-dollar market capitalization, reflecting strong investor optimism regarding its late-stage clinical biopharmaceutical pipeline.
Before European colonizers established a physical settlement, the land that became New Amsterdam—and eventually New York City—was inhabited for thousands of years by the indigenous Lenape people, who called the island region Lenapehoking or Manahatta...
Wall Street researchers covering NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) maintain a consensus 12-month price target averaging $51.71 to $52.24, with high individual estimates reaching up to $63.00 and lows near $38.00.
Obicetrapib is an investigational, low-dose oral CETP inhibitor developed to lower low-density lipoprotein cholesterol and reduce cardiovascular disease risk.
Walmart offers starting salaries of up to $110,000 in the first year for qualified long-haul and regional drivers joining its private truck fleet.
NewAmsterdam Pharma (a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic and cardiovascular diseases) operates as an independent public company listed on the Nasdaq stock exchange under the ticker symbol NAMS...
Obicetrapib, an investigational cholesteryl ester transfer protein inhibitor developed by NewAmsterdam Pharma for lowering low-density lipoprotein cholesterol, anticipates potential commercial availability following the completion of its rolling regu...
Determining whether any equity trading under the ticker symbol NAMS is a sound investment requires a thorough analysis of its underlying financial statements, industry sector performance, and competitive positioning.
NewAmsterdam Pharma Company N.V.
Obicetrapib functions as a potent, selective inhibitor of the cholesteryl ester transfer protein (CETP).
New Amsterdam concluded its television broadcast run following its final season on NBC, bringing the emotional medical drama series to a definitive narrative close.